Human Genome Epidemiology Literature Finder
|
Records 1 - 16 (of 16 Records) |
| Query Trace: Cardiovascular Diseases and CYP2C19[original query] |
|---|
| Effects of omeprazole and genetic polymorphism of CYP2C19 on the clopidogrel active metabolite. Drug metabolism and disposition: the biological fate of chemicals 2012 Jan 40 (1): 187-97. Boulenc Xavier, Djebli Nassim, Shi Juan, Perrin Laurent, Brian William, Van Horn Robert, Hurbin Fabri |
| Relationship between cytochrome P450 2C19*17 genotype distribution, platelet aggregation and bleeding risk in patients with blood stasis syndrome of coronary artery disease treated with clopidogrel. Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine 2012 Jun 10 (6): 647-54. Dai Ze-long, Chen Hui, Wu Xiao-yi |
| The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study. European heart journal 2012 Mar . Bhatt DL, Paré G, Eikelboom JW, Simonsen KL, Emison ES, Fox KA, Steg PG, Montalescot G, Bhakta N, Hacke W, Flather MD, Mak KH, Cacoub P, Creager MA, Berger PB, Steinhubl SR, Murugesan G, Mehta SR, Kottke-Marchant K, Lincoff AM, Topol EJ |
| Frequencies of 23 functionally significant variant alleles related with metabolism of antineoplastic drugs in the chilean population: comparison with caucasian and asian populations. Frontiers in genetics 2012 3 . Roco A, Quiñones L, Agúndez JA, García-Martín E, Squicciarini V, Miranda C, Garay J, Farfán N, Saavedra I, Cáceres D, Ibarra C, Varela N |
| The influence of genetic polymorphism of Cyp2c19 isoenzyme on the pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases. Journal of clinical pharmacology 2014 Aug 54 (8): 874-80. Kara?niewicz-?ada Marta, Danielak Dorota, Rubi? B?a?ej, Burchardt Pawe?, Oszkinis Grzegorz, G?ówka Francisz |
| [CLINICAL AND PHARMACOLOGICAL FACTORS INFLUENCING RESISTANCE TO CLOPIDOGREL IN PATIENTS WITH CARDIOVASCULAR DISEASES]. Klinicheskaia meditsina 2015 93 (2): 40-6. Mesitskaia D F, Nikitina Iu M, Kopylov F Iu, Syrkin A L, Aksenova M G, Kirillov M Iu, Dobrovol'ski? A |
| A Pharmacogenomic Dissection of a Rosuvastatin-Induced Rhabdomyolysis Case Evokes the Polygenic Nature of Adverse Drug Reactions. Pharmacogenomics and personalized medicine 2020 3 13 59-70. Calderon-Ospina Carlos Alberto, Hernández-Sómerson Mario, García Ana María, Mejia Adriana, Tamayo-Agudelo Caroll, Laissue Paul, Fonseca Mendoza Dora Jane |
| Coding SNPs in hsa-miR-1343-3p and hsa-miR-6783-3p target sites of CYP2C19 modulates clopidogrel response in individuals with cardiovascular diseases. Life sciences 2020 Jan 245 117364. Sharma Anu Radha, Vohra Manik, Shukla Vaibhav, Guddattu Vasudeva, Razak Uk Abdul, Shetty Ranjan, Umakanth Shashikiran, Satyamoorthy Kapaettu, Rai Padmalatha |
| Cardiovascular Pharmacogenomics: An Update on Clinical Studies of Antithrombotic Drugs in Brazilian Patients. Molecular diagnosis & therapy 2021 8 25 (6): 735-755. Hirata Thiago Dominguez Crespo, Dagli-Hernandez Carolina, Genvigir Fabiana Dalla Vecchia, Lauschke Volker Martin, Zhou Yitian, Hirata Mario Hiroyuki, Hirata Rosario Dominguez Cres |
| Analytical validation of GMEX rapid point-of-care CYP2C19 genotyping system for the CHANCE-2 trial. Stroke and vascular neurology 2021 5 6 (2): 274-279. Meng Xia, Wang Anxin, Zhang Guojun, Niu Siying, Li Wei, Han Sifei, Fang Fang, Zhao Xingquan, Dong Kehui, Jin Zening, Zheng Huaguang, Chen Kelin, Li Hao, Yang Chengyuan, Wang Yongj |
| Biochip-based approach for comprehensive pharmacogenetic testing. Drug metabolism and personalized therapy 2020 Dec . Ikonnikova Anna Yu, Filippova Marina A, Surzhikov Sergey A, Pozhitnova Victoria O, Kazakov Ruslan E, Lisitsa Tatiana S, Belkov Sergey A, Nasedkina Tatiana |
| Predicting the Effects of CYP2C19 and Carboxylesterases on Vicagrel, a Novel P2Y12 Antagonist, by Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling Approach. Frontiers in pharmacology 2021 1 11 591854. Liu Shuaibing, Wang Ziteng, Tian Xin, Cai Weim |
| Relationship between CYP2C19 Polymorphism and Clopidogrel Resistance in Patients with Coronary Heart Disease and Ischemic Stroke in China. Genetics research 2022 11 2022 1901256. Chang Rong, Zhou Wenqin, Ye Yi, Zhang Xiaofei, Liu Yanmin, Wu Jinch |
| CYP2C19 Polymorphism in Ischemic Heart Disease Patients Taking Clopidogrel After Percutaneous Coronary Intervention in Egypt. Journal of epidemiology and global health 2023 5 . Ahmed Shawky, Hussein Sabit, Mahmoud Nazih, Khalid Baraka, Mokhtar El-Zawah |
| Association of CYP2C19 Polymorphic Markers with Cardiovascular Disease Risk Factors in Gas Industry Workers Undergoing Periodic Medical Examinations. High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension 2023 2 . Sychev Dmitry Alekseevich, Polyakova Olga Alexandrovna, Sozaeva Zhannet Alimovna, Mirzaev Karin Badavievich, Ostroumova Olga Dmitriev |
| High Frequency of CYP2C19*3 Heterozygotes Among Patients Under Clopidogrel Treatment in Ouagadougou, Burkina Faso. Pakistan journal of biological sciences : PJBS 2024 9 27 (8): 398-403. Abdoul Karim Ouattara, Yves Donald Kagambega, Teega-Wende Clarisse Ouedraogo, Lassina Traore, Modeste Ouedraogo, Nobila Valentin Yameogo, Jacques Simpo |
- Page last reviewed:Feb 1, 2024
- Content source: